Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support

Brief summary

The purpose of this study was to evaluate the implementation of inclisiran in a regional primary care setting in the UK Inclisiran, also known as KJX839, is a medication made to reduce the level of "bad" cholesterol (LDL-cholesterol) in the blood. Inclisiran works in a way that makes the liver produce less of a substance called 'PCSK9'. PCSK9 reduces the ability of the liver to remove LDL-cholesterol from the blood. By lowering the production of PCSK9, Inclisiran leads to more LDL-cholesterol being removed by the liver from the blood, thereby reducing LDL-cholesterol overall.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

acronym

SPIRIT

status

COMPLETED

phase

PHASE3

study type

INTERVENTIONAL

enrollment

892

sponsor

Novartis Pharmaceuticals

conditions

Atherosclerotic Cardiovascular Disease; Atherosclerotic Cardiovascular Disease Risk Equivelents; Elevated Low Density Lipoprotein Cholesterol

interventions

DRUG: Inclisiran; BEHAVIORAL: Behavioural Support; DRUG: Background lipid lowering therapy

start date

2021-07-07

start date type

ACTUAL

primary completion date

2023-01-13

has results

true

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters